Voyager Therapeutics, Inc.
VYGR
$3.17
-$0.26-7.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -43.75% | -68.00% | 3.40% | -26.22% | -37.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.75% | -68.00% | 3.40% | -26.22% | -37.58% |
| Cost of Revenue | 28.13% | 35.17% | 45.17% | 52.02% | 54.96% |
| Gross Profit | -438.28% | -128.25% | -40.28% | -74.59% | -85.41% |
| SG&A Expenses | 4.38% | 0.27% | 9.18% | 12.59% | 9.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.96% | 25.41% | 34.52% | 39.88% | 39.83% |
| Operating Income | -480.67% | -165.99% | -79.08% | -107.62% | -118.26% |
| Income Before Tax | -3,511.56% | -148.11% | -49.38% | -89.95% | -102.33% |
| Income Tax Expenses | -4.18% | -52.77% | 50.00% | -12.32% | -0.28% |
| Earnings from Continuing Operations | -2,682.29% | -149.12% | -50.52% | -90.58% | -103.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,682.29% | -149.12% | -50.52% | -90.58% | -103.08% |
| EBIT | -480.67% | -165.99% | -79.08% | -107.62% | -118.26% |
| EBITDA | -656.32% | -159.93% | -70.14% | -101.95% | -112.77% |
| EPS Basic | -8,479.41% | -134.79% | -43.86% | -86.70% | -100.71% |
| Normalized Basic EPS | -174,740.00% | -132.62% | -43.02% | -85.76% | -100.03% |
| EPS Diluted | -3,033.05% | -136.79% | -41.55% | -87.47% | -102.06% |
| Normalized Diluted EPS | -4,227.72% | -134.11% | -40.45% | -86.40% | -101.45% |
| Average Basic Shares Outstanding | 23.03% | 34.11% | 30.08% | 25.73% | 20.84% |
| Average Diluted Shares Outstanding | 22.32% | 32.09% | 29.55% | 24.41% | 19.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |